^
    7d
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    10d
    HCW9218 for Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=21, Completed, ImmunityBio, Inc. | Active, not recruiting --> Completed | N=60 --> 21
    Trial completion • Enrollment change
    |
    HCW9218
    18d
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Baylor College of Medicine | N=24 --> 14
    Enrollment change
    |
    GPC3 (Glypican 3) • IL15 (Interleukin 15)
    |
    AGAR T cells
    21d
    A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SAR445877
    30d
    HCW9218 in Select Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Completed, Masonic Cancer Center, University of Minnesota | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025
    Trial completion • Trial completion date
    |
    HCW9218
    1m
    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=542, Recruiting, Sanofi | N=291 --> 542 | Trial completion date: Nov 2028 --> Jun 2028
    Enrollment change • Trial completion date • First-in-human
    |
    MSI (Microsatellite instability)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Yervoy (ipilimumab) • SAR445877 • muzastotug (ADG126)
    2ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Feb 2040 --> Aug 2040
    Enrollment closed • Trial completion date
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    2ms
    ACTM-838-01: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Terminated, Actym Therapeutics, Inc. | N=35 --> 10 | Trial completion date: Jul 2026 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Aug 2025; Sponsor's strategic business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ACTM-838
    2ms
    ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response. (PubMed, Oncotarget)
    Single-cell RNAseq and flow cytometry data confirmed activation and infiltration of both innate and adaptive immune cells. ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • TGFB1 (Transforming Growth Factor Beta 1) • IFNA1 (Interferon Alpha 1) • IL15 (Interleukin 15)
    |
    ACTM-838
    2ms
    A quantitative systems pharmacology model to inform clinical translation of dynamic PKPD relationships of engineered IL-15. (PubMed, Eur J Pharm Sci)
    In this work, we develop a quantitative systems pharmacology (QSP) model to capture the dynamics of lymphocyte expansion in response to three engineered IL-15/IL-15Rα therapeutics: a potency engineered Fc-fusion referred to as Efbalropendekin alfa; a heterodimeric, PD-1 targeted cytokine assessed in non-clinical studies (PD1/IL15 TaCk); and an anti-respiratory syncytial virus targeted cytokine that serves as a non-binding isotype control (RSV/IL15 TaCk)...Finally, we leverage our QSP modeling framework to generate virtual cohorts with various translational scenarios to make clinical PK/PD predictions in response to PD1/IL15 TaCk treatment. Overall, the systems modeling presented herein offers a novel approach to integrate non-clinical datasets, aid in translation, and support dosing decisions for cytokine-based therapies that activate the immune system and display a dynamic PK/PD relationship.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL15 (Interleukin 15)
    2ms
    Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies. (PubMed, Gut)
    These early-phase findings suggest that VG161 elicits meaningful immune activation in ICC and supports further investigation. By inducing both direct oncolysis and multilayered immune activation, VG161 shows clinical benefit in a heavily pretreated population and holds promise for integration with CPI-based regimens. Validation in larger trials is warranted.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
    |
    5-fluorouracil • leucovorin calcium • VG161
    3ms
    Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jun 2039 --> Jun 2044 | Trial primary completion date: May 2025 --> May 2030
    Trial completion date • Trial primary completion date
    |
    IL15 (Interleukin 15)
    |
    cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells